

Generics North America (NAFTA) Industry Guide 2019-2028

Industry Report | 2024-12-20 | 220 pages | MarketLine

AVAILABLE LICENSES:

- Single user licence (PDF) \$795.00
- Site License (PDF) \$1192.00
- Enterprisewide license (PDF) \$1590.00

Report description:

Generics North America (NAFTA) Industry Guide 2019-2028

Summary

The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume, and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of \$88,125.3 million in 2023. The Canada was the fastest growing country, with a CAGR of 7% over the 2019-23 period.
- Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of \$74,229.0 million in 2023. This was followed by Canada and Mexico, with a value of \$7,717.8 and \$6,178.6 million, respectively.
- The US is expected to lead the generics industry in the NAFTA bloc, with a value of \$98,531.3 million in 2028, followed by Canada and Mexico with expected values of \$10,446.0 and \$7,720.0 million, respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market
- Leading company profiles reveal details of key generics market players' NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume

- Compares data from the US, Canada and Mexico, alongside individual chapters on each country

Reasons to Buy

- What was the size of the NAFTA generics market by value in 2023?
- What will be the size of the NAFTA generics market in 2028?
- What factors are affecting the strength of competition in the NAFTA generics market?
- How has the market performed over the last five years?
- How large is the NAFTA generics market in relation to its regional counterparts?

Table of Contents:

Table of Contents

- 1 Introduction
- 1.1. What is this report about?
- 1.2. Who is the target reader?
- 1.3. How to use this report
- 1.4. Definitions
- 2 NAFTA Generics
- 2.1. Industry Outlook
- 3 Generics in Canada
- 3.1. Market Overview
- 3.2. Market Data
- 3.3. Market Segmentation
- 3.4. Market outlook
- 3.5. Five forces analysis
- 4 Macroeconomic Indicators
- 4.1. Country data
- 5 Generics in Mexico
- 5.1. Market Overview
- 5.2. Market Data
- 5.3. Market Segmentation
- 5.4. Market outlook
- 5.5. Five forces analysis
- 6 Macroeconomic Indicators
- 6.1. Country data
- 7 Generics in The United States
- 7.1. Market Overview
- 7.2. Market Data
- 7.3. Market Segmentation
- 7.4. Market outlook
- 7.5. Five forces analysis
- 8 Macroeconomic Indicators
- 8.1. Country data
- 9 Company Profiles
- 9.1. Teva Pharmaceutical Industries Ltd
- 9.2. Viatris Inc
- 9.3. Sun Pharmaceutical Industries Ltd

Scotts International. EU Vat number: PL 6772247784

- 9.4. Novartis AG
- 9.5. Sandoz Group AG
- 9.6. Hikma Pharmaceuticals Plc
- 9.7. Sanofi
- 9.8. Les Laboratoires Servier SAS
- 9.9. Stada Arzneimittel AG
- 9.10. Bayer AG
- 9.11. Lupin Ltd
- 9.12. Aspen Pharmacare Holdings Ltd
- 9.13. EMS SA
- 9.14. Eurofarma Laboratorios SA
- 9.15. Ache Laboratorios Farmaceuticos SA
- 9.16. Apotex Inc
- 9.17. Teva Canada Ltd
- 9.18. Sandoz Canada Inc
- 9.19. CSPC Pharmaceutical Group Ltd
- 9.20. Sino Biopharmaceutical Ltd
- 9.21. Hansoh Pharmaceutical Group Co Ltd
- 9.22. Dr. Reddy's Laboratories Ltd
- 9.23. Cipla Ltd
- 9.24. Aurobindo Pharma Ltd
- 9.25. PT Kalbe Farma Tbk
- 9.26. PT Indofarma Tbk
- 9.27. PT Sanbe Farma
- 9.28. PT Soho Global Health Tbk
- 9.29. Friulchem SpA
- 9.30. DOC Generici SRL
- 9.31. Recordati SpA
- 9.32. Daiichi Sankyo Co Ltd
- 9.33. Towa Pharmaceutical Co Ltd
- 9.34. Sawai Group Holdings Co Ltd
- 9.35. Toho Holdings Co Ltd
- 9.36. Laboratorios Silanes SA de CV
- 9.37. Pfizer Inc
- 9.38. Biocad
- 9.39. R-Pharm
- 9.40. Pharmstandard
- 9.41. AstraZeneca Plc
- 9.42. Bluefish Pharmaceuticals AB
- 9.43. Navamedic ASA
- 9.44. Novartis International AG
- 9.45. Beacons Pharmaceuticals Pte Ltd
- 9.46. Abbott Laboratories SA
- 9.47. Adcock Ingram Holdings Ltd
- 9.48. Dongkook Pharmaceutical Co Ltd
- 9.49. JW Holdings Corp
- 9.50. Hanmi Pharmaceuticals Co Ltd

Scotts International. EU Vat number: PL 6772247784

- 9.51. Dong Wha Pharma Co Ltd
- 9.52. Esteve Pharmaceuticals SA
- 9.53. Abdi Ibrahim Ilac Sanayi ve Ticaret AS
- 9.54. Deva Holding AS
- 9.55. Sandoz Inc
- 10 Appendix
- 10.1. Methodology
- 10.2. About MarketLine



☐ - Print this form

To place an Order with Scotts International:

Complete the relevant blank fields and sign

Generics North America (NAFTA) Industry Guide 2019-2028

Industry Report | 2024-12-20 | 220 pages | MarketLine

Select license	License			Price
	Single user licence (PDF)			\$795.00
	Site License (PDF)			\$1192.00
	Enterprisewide license (PI	OF)		\$1590.00
				VAT
				Total
Email*		Phone*		
irst Name*		Last Name*		
ob title*				
		EU Vat / Tax ID /	NIP number*	
Company Name*		EU Vat / Tax ID /	NIP number*	
Company Name* Address*			NIP number*	
lob title* Company Name* Address* Zip Code*		City*	NIP number* 2025-05-04	

Scotts International. EU Vat number: PL 6772247784